J&JPRD yet to review approvable letter and finalize label with FDA.

Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) received an approvable letter regarding two sNDAs for Risperdal®. The sNDAs are for the treatment of schizophrenia in adolescents between 13-17 years and for the short-term treatment of bipolar mania associated with bipolar I disorder in children and adolescents between 10-17 years.

The FDA has not asked for any additional studies, according to J&JPRD. The company says that it is currently reviewing the letter and then will finalize the label with FDA.

Risperdal is already approved for the treatment of bipolar I disorder and acute to manic or mixed episodes associated with bipolar mania.

Previous articleLAB Licenses Breakthrough Cancer Pain Therapy to Janssen Pharmaceutica in Europe and Africa
Next articleGenzyme Gains Marketing Rights for Ceregene’s Parkinson’s Drug in $150M Deal